Commonwealth Equity Services LLC Grows Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Commonwealth Equity Services LLC lifted its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Rating) by 46.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 27,186 shares of the company’s stock after buying an additional 8,614 shares during the quarter. Commonwealth Equity Services LLC’s holdings in Intellia Therapeutics were worth $948,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently modified their holdings of NTLA. MetLife Investment Management LLC increased its position in shares of Intellia Therapeutics by 54.7% during the first quarter. MetLife Investment Management LLC now owns 37,362 shares of the company’s stock valued at $2,715,000 after buying an additional 13,209 shares during the period. Rhumbline Advisers increased its position in shares of Intellia Therapeutics by 2.7% during the first quarter. Rhumbline Advisers now owns 98,247 shares of the company’s stock valued at $7,140,000 after buying an additional 2,620 shares during the period. Cibc World Market Inc. increased its position in shares of Intellia Therapeutics by 47.3% during the first quarter. Cibc World Market Inc. now owns 4,740 shares of the company’s stock valued at $344,000 after buying an additional 1,522 shares during the period. Blair William & Co. IL increased its position in shares of Intellia Therapeutics by 11.9% during the first quarter. Blair William & Co. IL now owns 10,362 shares of the company’s stock valued at $753,000 after buying an additional 1,100 shares during the period. Finally, Canada Pension Plan Investment Board purchased a new position in shares of Intellia Therapeutics during the first quarter valued at about $307,000. Hedge funds and other institutional investors own 85.61% of the company’s stock.

Wall Street Analysts Forecast Growth

NTLA has been the topic of several research analyst reports. Raymond James reduced their price target on shares of Intellia Therapeutics from $124.00 to $94.00 and set an “outperform” rating on the stock in a research report on Friday, February 24th. StockNews.com began coverage on shares of Intellia Therapeutics in a research note on Thursday, May 18th. They set a “sell” rating on the stock. Oppenheimer dropped their price objective on shares of Intellia Therapeutics from $115.00 to $93.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th. Chardan Capital dropped their price objective on shares of Intellia Therapeutics from $129.00 to $111.00 and set a “buy” rating on the stock in a research note on Friday, February 24th. Finally, Credit Suisse Group dropped their price objective on shares of Intellia Therapeutics from $88.00 to $76.00 and set an “outperform” rating on the stock in a research note on Friday, February 24th. One analyst has rated the stock with a sell rating, three have given a hold rating and sixteen have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $86.06.

Intellia Therapeutics Stock Up 5.6 %

Shares of Intellia Therapeutics stock opened at $44.39 on Tuesday. The company has a market cap of $3.91 billion, a price-to-earnings ratio of -8.24 and a beta of 1.86. The company’s 50 day moving average is $38.95 and its 200 day moving average is $40.52. Intellia Therapeutics, Inc. has a twelve month low of $32.44 and a twelve month high of $76.45.

Intellia Therapeutics (NASDAQ:NTLA – Get Rating) last issued its quarterly earnings data on Thursday, May 4th. The company reported ($1.17) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.41) by $0.24. The company had revenue of $12.60 million for the quarter, compared to the consensus estimate of $11.76 million. Intellia Therapeutics had a negative net margin of 804.94% and a negative return on equity of 41.67%. The firm’s revenue for the quarter was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.96) earnings per share. Sell-side analysts expect that Intellia Therapeutics, Inc. will post -5.34 EPS for the current fiscal year.

Intellia Therapeutics Profile

(Get Rating)

Intellia Therapeutics, Inc is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.